Quest Diagnostics Incorporated (DGX) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.036x

Based on the latest financial reports, Quest Diagnostics Incorporated (DGX) has a cash flow conversion efficiency ratio of 0.036x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($278.00 Million) by net assets ($7.67 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Quest Diagnostics Incorporated (DGX) net asset quality to measure how much of total assets are equity-financed.

Quest Diagnostics Incorporated - Cash Flow Conversion Efficiency Trend (1996–2025)

This chart illustrates how Quest Diagnostics Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DGX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Quest Diagnostics Incorporated Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Quest Diagnostics Incorporated ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Yihai Kerry Arawana Holdings Co Ltd
SHE:300999
0.137x
SK Holdings Co Ltd
KO:034730
0.007x
Accelink Technologies Co Ltd
SHE:002281
0.114x
BCE Inc
TO:BCE
0.084x
Jiangsu Hengli Hydraulic Co Ltd
SHG:601100
0.021x
AXIA Energia
NYSE:AXIA
0.039x
Hapag Lloyd AG
XETRA:HLAG
0.022x
Pan American Silver Corp
TO:PAAS
0.069x

Annual Cash Flow Conversion Efficiency for Quest Diagnostics Incorporated (1996–2025)

The table below shows the annual cash flow conversion efficiency of Quest Diagnostics Incorporated from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see DGX company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $7.29 Billion $1.89 Billion 0.259x +33.81%
2024-12-31 $6.90 Billion $1.33 Billion 0.193x -2.40%
2023-12-31 $6.42 Billion $1.27 Billion 0.198x -30.70%
2022-12-31 $6.01 Billion $1.72 Billion 0.286x -15.95%
2021-12-31 $6.56 Billion $2.23 Billion 0.340x +16.96%
2020-12-31 $6.89 Billion $2.00 Billion 0.291x +34.90%
2019-12-31 $5.76 Billion $1.24 Billion 0.216x -3.95%
2018-12-31 $5.34 Billion $1.20 Billion 0.225x -3.78%
2017-12-31 $5.04 Billion $1.18 Billion 0.233x +3.41%
2016-12-31 $4.74 Billion $1.07 Billion 0.226x +33.26%
2015-12-31 $4.78 Billion $810.00 Million 0.169x -21.82%
2014-12-31 $4.33 Billion $938.00 Million 0.217x +32.00%
2013-12-31 $3.97 Billion $652.00 Million 0.164x -42.13%
2012-12-31 $4.19 Billion $1.19 Billion 0.284x +17.65%
2011-12-31 $3.71 Billion $895.50 Million 0.241x -12.59%
2010-12-31 $4.05 Billion $1.12 Billion 0.276x +10.91%
2009-12-31 $4.01 Billion $997.40 Million 0.249x -15.69%
2008-12-31 $3.60 Billion $1.06 Billion 0.295x +5.76%
2007-12-31 $3.32 Billion $926.92 Million 0.279x -11.56%
2006-12-31 $3.02 Billion $951.90 Million 0.315x +2.29%
2005-12-31 $2.76 Billion $851.58 Million 0.308x -11.69%
2004-12-31 $2.29 Billion $798.78 Million 0.349x +26.10%
2003-12-31 $2.39 Billion $662.80 Million 0.277x -17.91%
2002-12-31 $1.77 Billion $596.37 Million 0.337x -3.30%
2001-12-31 $1.34 Billion $465.80 Million 0.349x -2.63%
2000-12-31 $1.03 Billion $369.45 Million 0.358x +23.87%
1999-12-31 $863.10 Million $249.50 Million 0.289x +16.10%
1998-12-31 $567.90 Million $141.40 Million 0.249x -23.50%
1997-12-31 $541.70 Million $176.30 Million 0.325x +298.14%
1996-12-31 $538.72 Million $-88.49 Million -0.164x --

About Quest Diagnostics Incorporated

NYSE:DGX USA Diagnostics & Research
Market Cap
$26.11 Billion
Market Cap Rank
#1248 Global
#516 in USA
Share Price
$235.84
Change (1 day)
+0.91%
52-Week Range
$173.49 - $235.94
All Time High
$235.94
About

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagn… Read more